Pharma Focus Asia

Lek Invests US$400 mn for the Construction of Biopharmaceutical Production Centre in Slovenia, Europe


Lek will invest US$400 million for the construction of an advanced biopharmaceutical production centre in Slovenia, Europe.


The facility will feature cutting-edge production and storage facilities, with a combined surface area totalling 40,000 square metres.

The first of three facilities planned at Lek's current site in Lendava will be dedicated to producing energy products for the ongoing production while also addressing the future centre's demands for the production of drug substances used in biosimilars.

The new biosimilars production centre will enhance manufacturing capabilities and provide crucial support to propel the future expansion of the global biosimilar portfolio. 

Once fully operational, the site will play a vital role in producing the necessary drug substances for biosimilars, catering to the treatment needs of patients in the areas of rheumatology, oncology, and immunology.

The facility is anticipated to commence operations by the end of 2026.


Name        Lek
Type          New Construction
Budget     US$400 million
Year          2026

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference